This is the most underrated research combo on ER.
We stacked these to hit two different layers of the same problem. Aging neural tissue that is running on fewer, less efficient mitochondria.
J-147 is a curcumin-derived small molecule developed for neurodegeneration. It binds the a-F1 subunit of mitochondrial ATP synthase (ATP5A). That mild modulation raises intracellular calcium, activates CAMKK2, and feeds into AMPK/mTOR signaling. Downstream you get acetyl-CoA pathway shifts, lower ACC1 activity, BDNF/NGF support and neuroprotective signaling that shows up in aged and Alzheimer's models as better memory, synaptic preservation and less inflammatory load. It also was designed to specificaly cross the BBB.
PQQ drives mitochondrial biogenesis through PGC-1a, NRF-1, NRF-2, and TFAM. So you are not only tuning existing ATP machinery, you are increasing mitochondrial number and quality. It redox-cycles thousands of times as an antioxidant, supports NGF and in human data around 10-20 mg/day has been associated with improved fatigue and notable gains in memory and cognitive flexibility over 8 weeks.
Together:
PQQ increases mitochondrial capacity
J-147 modulates ATP synthase and neuroprotective signaling inside that capacity
Research only. Not medical advice.